Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S. Koreans Report New Drug To Suppress Key Liver Cancer Protein

This article was originally published in PharmAsia News

Executive Summary

South Korean researchers say they have developed a treatment capable of suppressing the protein behind much liver cancer. A published study said the TSAHC treatment is aimed at TM4SF5, the protein already known to be a major cause of the cancer. The substance, which is about to enter clinical trials in South Korea and the United States, has shown to have fewer side effects than drugs already available. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel